Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Jules Meijerink

Principal Investigator
Jules Meijerink

Dr. Jules Meijerink joined the Princess Maxima Center in 2016 as a senior principal investigator. His research group focuses on physiologic and pathogenic dependencies that drive disease development, therapy resistance and relapse as treatment targets for future therapies for children with T-cell leukemia or lymphomas.


Dr. Jules Meijerink obtained his MSc degree in Medical and Biochemical Biology at the University of Nijmegen in 1990. Het started his PhD study in 1991 at the Department of Hematology (Head Prof. Dr. Theo de Witte) of the University of Nijmegen.  As visiting research fellow, he received a one-year traineeship in the lab of Prof. Stanley J. Korsmeyer at the Howard Hughes Medical Institute of the Washington University of Medicine in St. Louis in the USA in 1995. In 1997, he obtained his PhD degree at the Faculty of Medicine of the University of Nijmegen on the role of the BCL2 gene family in malignant hematopoiesis and their use for monitoring of disease. From 1996 onwards, he started his own research line at the Department of Hematology of the University of Nijmegen on the role of BCL2 family members in malignant hematopoiesis and chemotherapy-resistance of low-grade lymphomas and myelodysplastic syndromes that led to two completed PhD studies. In 2000, he became senior scientist at the Department of Pediatrics (Division of Pediatric Oncology/Hematology (Head: Prof. Dr. Rob Pieters) of the Erasmus Medical Center-Sophia Children’s Hospital in Rotterdam, the medical faculty of the Erasmus University in Rotterdam. He was appointed principal investigator and staff member in 2001. His research was focused on the identification of molecular-cytogenetic abnormalities in pediatric T-cell acute lymphoblastic leukemia (T-ALL) and their role in pathogenesis and treatment response. In 2007 he was appointed Associate Professor (UHD) at this medical faculty in molecular-cytogenetic pediatric oncology. This led to 8 completed PhD thesis studies. He started as senior Principal Investigator at the Princess Maxima center for Pediatric Oncology in 2016.